Beijing Tong Ren Tang Chinese Medicine Management
Management criteria checks 1/4
Beijing Tong Ren Tang Chinese Medicine's CEO is Fei Chen, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is HK$2.18M, comprised of 60.8% salary and 39.2% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth HK$399.29K. The average tenure of the management team and the board of directors is 0.3 years and 2.9 years respectively.
Key information
Fei Chen
Chief executive officer
HK$2.2m
Total compensation
| CEO salary percentage | 60.8% |
| CEO tenure | less than a year |
| CEO ownership | 0.005% |
| Management average tenure | less than a year |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk
Feb 05
Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Jan 03A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Sep 28Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today
Jul 12Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?
Mar 29Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28
Apr 28Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28
Mar 25Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?
Oct 27Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 28Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Mar 11What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Feb 04Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?
Jan 18
Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?
Dec 29Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Dec 11Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | HK$540m |
| Sep 30 2023 | n/a | n/a | HK$619m |
| Jun 30 2023 | n/a | n/a | HK$697m |
| Mar 31 2023 | n/a | n/a | HK$672m |
| Dec 31 2022 | HK$2m | HK$1m | HK$646m |
| Sep 30 2022 | n/a | n/a | HK$601m |
| Jun 30 2022 | n/a | n/a | HK$555m |
| Mar 31 2022 | n/a | n/a | HK$582m |
| Dec 31 2021 | HK$1m | HK$1m | HK$608m |
Compensation vs Market: Fei's total compensation ($USD277.95K) is below average for companies of similar size in the Hong Kong market ($USD520.90K).
Compensation vs Earnings: Fei's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Fei Chen (52 yo)
less than a year
Tenure
HK$2,176,000
Compensation
Mr. Fei Chen serves as Acting Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited since March 28, 2024. She serves as Executive Director and until April 19, 2023 served as Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO | less than a year | HK$2.18m | 0.0051% HK$ 399.3k | |
| Executive Chairman of the Board | less than a year | no data | no data | |
| CFO & Company Secretary | 3.9yrs | no data | no data | |
| Deputy GM & General Counsel | no data | no data | no data |
0.3yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 3613's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO | 4.1yrs | HK$2.18m | 0.0051% HK$ 399.3k | |
| Executive Chairman of the Board | less than a year | no data | no data | |
| Independent Non-Executive Director | 6.6yrs | HK$264.00k | no data | |
| Independent Non-Executive Director | 11yrs | HK$264.00k | no data | |
| Non-Executive Director | 1.7yrs | no data | no data | |
| Independent Non-Executive Director | 1.1yrs | no data | no data |
2.9yrs
Average Tenure
54.5yo
Average Age
Experienced Board: 3613's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.